• FRONT MATTER R1-R8

• CONTENTS R9-R10

• INTRODUCTION 1-1

• ARI AND MENINGOCOCCAL MENINGITIS IN THE DEVELOPING WORLD 2-4

• DETERMINING VACCINE NEED 5-7

• OVERCOMING SCIENTIFIC AND TECHNOLOGICAL BARRIERS 8-13

• PROVING VACCINE EFFICACY: THE CHALLENGE OF DEVELOPING-COUNTRY FIELD TRIALS 14-19

• INTRODUCING AN EFFECTIVE VACCINE 20-26

• Involving the U.S. Public and Private Sectors in the CVI 27-27

• BRINGING CLARITY TO THE CVI VISION 28-28

• TRENDS IN THE GLOBAL VACCINE SITUATION 29-30

• RESHAPING THE EPI 31-31

• A ROLE FOR INDUSTRY 32-34

• FACILITATING GREATER U.S. INVOLVEMENT 35-38

• DISCUSSION SUMMARY 39-40

• APPENDIX A: PROMISE AND PROBLEMS . . . (FINAL AGENDA, LIST OF SPEAKERS AND PARTICIPANTS) 41-48

• APPENDIX B: INVOLVING THE U.S. PUBLIC AND PRIVATE SECTORS IN THE CVI . . . (FINAL AGENDA, LIST OF SPEAKERS AND PARTICIPANTS) 49-54

• APPENDIX C: ACRONYMS AND ABBREVIATIONS 55-56

" FRONT MATTER ." The Children's Vaccine Initiative: Continuing Activities . Washington, DC: The National Academies Press, 1995 .

Please select a format: